A Unique Candlelight Concert in the Middle of the Desert Set in the Exclusive Location of the Archaeological Site of Hegra, the UNESCO World Heritage Site
29.12.2021 16:03:00 EET | Business Wire | Press release
A new magical experience has just lit up in the middle of the desert. People could live a unique emotion by attending the Candlelight Concert, an atmospheric musical performance set in the archaeological site of Hegra (AlUla, Saudi Arabia), the UNESCO World Heritage Site famous for having more than 100 monumental tombs carved from rock formations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211229005155/en/
Hegra Candlelight Classic ph.Emad Alhusayni Balich Wonder Studio
The archaeological site, just 22 minutes far from the city of AlUla, has never been used for concerts of such intimate character.
The first concert that took place on the 24th December 2021 and the next one that will take place on the 31st December 2021 are produced by Balich Wonder Studio , the live entertainment group, leader in the creation and production of large-scale ceremonies, events and shows, brand and territorial experiences worldwide.
The audience live a full emotional experience by listening to the evocative repertoire performed live by the Stefan Lombard ensemble (piano, violin, cello and oud). The famous South African musical Director has created a suite (a collection of short musical pieces) from classic compositions to contemporary, Arab, movie soundtracks and a revised take on pop music.
More than 500 high-tech candles are the magic surrounding of these musical performances: sculpted by hand, they allow spectacular graphic patterns that emotionally enhance the special moments by blending harmoniously with the forms of the archaeological site, creating a landmark that merges the suggestions of the past and the dynamic of the contemporary.
The events exploit the latest technologies as the candles thanks to their various control possibilities, can shine all night, cozily shaping the surrounding and could reach four times the brightness of a traditional candle without burning or melting: the unique color combination allows for the same warmth as a real flame candle. In addition, its innovative algorithm can make an entire set of candles flicker differently, just like real candles would.
These two special events are exclusive occasions within the suggestive AlUla Moments Season, specifically designed for ‘Winter At Tantora’. The whole season is filled with high-end cultural, musical, wellness and arts events, as well as star-studded concerts, adventurous activities and immersive heritage experiences. BWS-KSA, the branch of the Balich Wonder Studio group based in Saudi Arabia, has been appointed by the Royal Commission for AlUla to produce multiple activities throughout the entire season that will enfold in late March.
The area and the city of AlJadidah has become an exclusive gathering spot, divided in various hubs where different cultures from all over the world, itinerant performing artists and the best of the circus arts will mix and mingle in the spirit of nomadic culture and the traditional Saudi Arabian hospitality with the aim to attract the widest audience and be inclusive.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005155/en/
Contact information
Balich Wonder Studio
Elettra Zadra
elettra.zadra@balichws.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom